These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16336322)

  • 21. Fulminant hepatic failure associated with bicalutamide.
    Dawson LA; Chow E; Morton G
    Urology; 1997 Feb; 49(2):283-4. PubMed ID: 9037299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
    Nuttall MC; Harris JP; Dawkins GP
    BJU Int; 2007 Feb; 99(2):243-4. PubMed ID: 17313420
    [No Abstract]   [Full Text] [Related]  

  • 24. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
    Kirby R
    Nat Clin Pract Urol; 2005 Jun; 2(6):304-8. PubMed ID: 16474813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case study: management of advanced prostate cancer with soft tissue metastases.
    Kirby R
    Prostate Cancer Prostatic Dis; 2005; 8(3):290-2. PubMed ID: 15940287
    [No Abstract]   [Full Text] [Related]  

  • 27. Combined androgen blockade: an update.
    Klotz L
    Urol Clin North Am; 2006 May; 33(2):161-6, v-vi. PubMed ID: 16631454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
    Takeshita H; Kawakami S; Fukui I
    Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
    [No Abstract]   [Full Text] [Related]  

  • 29. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A; Penson D; Dewilde S; Kleinman L
    Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hot flashes.
    Engstrom C
    Clin J Oncol Nurs; 2006 Aug; 10(4):533-5. PubMed ID: 16927907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing toxicity of hormonal therapy for prostate cancer.
    Klein E; Drecier R
    Cancer Invest; 2000; 18(7):687-8. PubMed ID: 11036477
    [No Abstract]   [Full Text] [Related]  

  • 37. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 38. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.